Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals

• Status: Recruiting
• Trial end date: 2023-03-15
• Target enrollment: 0
• Participant gender: All

Summary

There is currently no consensus on the adequate concomitant treatment to apomorphine pump in Parkinson's disease (PD). In practice, some centers withdraw all dopaminergic agonists when initiating apomorphine pump therapy, whereas others combine the two. To date, there has been no study led to determine the best strategy for efficiently treating motor and nonmotor symptoms, as well as improving patients' quality of life (QoL). This preliminary study, entitled AGAPO, aims at identifying significant differences in patients' evolution (nonmotor symptoms and quality of life), over a course of 6 months, depending on the two strategies adopted in French centers (apomorphine pump with or without dopaminergic agonists), through the Non Motor Symptoms Scale (NMSS, Chaudhuri et al, 2017).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rennes University Hospital
• Treatments: Apomorphine; Dopamine; Dopamine Agents; Dopamine Agonists

Criteria

Inclusion Criteria:

• Adults aged = or > 18 years,

• Idiopathic PD (According to British Brain Bank Criteria) without any other known or suspected cause of symptoms,

• Indicated for apomorphine pump therapy and according to the centers' practice, treatment with apomorphine pump association with dopamine agonists or apomorphine pump therapy alone

• Presence of fluctuations for > 3 years,

• Patients covered with social insurance.

• Written informed consent

Exclusion Criteria:

• Neurological (other than Parkinson's disease) or severe psychiatric history (depression, schizophrenia, addiction, bipolar disorder, anxiety and depressive disorders);

• Severe neurocognitive disorders (DSM-V)

• History of use of apomorphine pump treatment or deep brain stimulation or lesional surgery for PD or intrajejunal L-Dopa;

• History or current drug or alcohol abuse or dependencies;

• History of impulse control disorders;

• Adults legally protected (under judicial protection, guardianship or supervision), persons deprived of their liberty;

• Inability to understand the information given on the study, to express informed consent.